Camptothecin Derivatives with Localized Structural Modifications
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-tumor drugs, particularly camptothecin derivatives, suffer from low specificity and toxicity issues, limiting their effectiveness in treating various cancers, with many patients in China lacking access to advanced treatments due to economic and supply constraints.
Innovation Solution
Development of novel camptothecin derivatives with specific structural modifications, such as introducing groups at the C-7 and C-9 positions, like 9-t-butyloxyethyloxime-10-[(4'-piperidinyl)piperidinyl]carbonyloxy-camptothecin, which form pharmaceutically acceptable salts for improved solubility and reduced toxicity, are used to create pharmaceutical compositions for oral and injection administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If camptothecin is used to inhibit DNA topoisomerase I, then anti-tumor activity is achieved, but low specificity results in hematuria and bone marrow suppression
Solution Approach 1:
The patent applies local quality by introducing specific substituent groups at particular positions (C-7, C-9, C-20) of the camptothecin molecule. Each position receives tailored modifications: C-7 position gets groups like ethyl or N-t-butyloxymethyloxime, C-9 position gets groups like propenyl or dimethylaminomethyl, and C-20 position gets carboxymethyl or phenylalanine-carbonyloxy groups. These localized structural changes enhance anti-tumor specificity while reducing off-target toxicity effects such as hematuria and bone marrow suppression.
Solution Approach 2:
The patent creates composite molecular structures by combining the camptothecin core with various functional groups and substituents. The resulting compounds are hybrid molecules that integrate the anti-tumor activity of camptothecin with the beneficial properties of introduced groups, such as improved solubility, enhanced stability, and reduced toxicity. This composite approach allows simultaneous achievement of high anti-tumor efficacy and reduced harmful side effects.
2Reliability
If structural modifications are made at C-7 and C-9 positions to increase specificity and reduce toxicity, then anti-tumor efficacy is improved, but the complexity of synthesis increases
Solution Approach 1:
The patent applies segmentation by dividing the molecular modification process into distinct stages corresponding to different positions on the camptothecin molecule. The synthesis is segmented into modifying C-7 position, C-9 position, and C-20 position separately, allowing each modification to be optimized independently. This segmented approach manages synthesis complexity by breaking down the overall complex transformation into manageable sequential steps.
Solution Approach 2:
The patent employs parameter changes by systematically varying the chemical groups introduced at each position to optimize the balance between efficacy and toxicity. Different substituent parameters (type, size, lipophilicity) are tested at C-7, C-9, and C-20 positions to find the optimal combination that achieves high specificity and reduced toxicity while maintaining synthetic feasibility.
3Adaptability or versatility
If lipophilic groups are introduced to pass through blood brain barrier, then brain tumor treatment capability is improved, but solubility may be reduced
Solution Approach 1:
The patent applies local quality by strategically introducing lipophilic groups at specific positions (C-7, C-9, C-20) to enhance blood-brain barrier penetration. For example, N-t-butyloxymethyloxime group at C-7 and propenyl group at C-9 provide lipophilic character for BBB crossing. Simultaneously, other positions are modified with groups that maintain or improve solubility, creating a balanced molecular structure with localized functional properties.
Solution Approach 2:
The patent creates composite molecular structures that combine lipophilic groups for BBB penetration with hydrophilic or amphoteric groups for solubility. The resulting compounds are molecular composites with dual characteristics: lipophilic portions (e.g., t-butyloxymethyl, propenyl) enable blood-brain barrier crossing, while other portions (e.g., carboxymethyl, phenylalanine-carbonyloxy) maintain adequate solubility for pharmaceutical use.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Disclosed are novel camptothecin derivatives having anti-tumor activity (the basic structure thereof is as shown in the figure) and compositions of such compounds and use thereof. The compounds according to the present invention exhibit very good water solubility and stability, show good selectivity among drugs of the same category, and have a very high therapeutic index. Such compounds are promising as therapeutic agents for treating tumors.